Patients with Chronic Fatigue Syndrome (CFS) often report a comorbid depressive disorder. Comorbid depression may negatively influence the long-term outcome of CFS therefore it must be correctly diagnosed and treated. The aim of the present study is to provide a clinical and psychometric assessment of CFS patients with and without depressive features. A comparative analysis between 57 CFS subjects (CDC, 1994), 17 of whom with a comorbid depression, and 55 matched healthy volunteers was assessed to evaluate the presence of any psychophysical distress and alexithymic traits, by means of Symptom Checklist-90-R (SCL-90R) and Toronto Alexithymia Scale (TAS-20). The severity of fatigue was also assessed in all CFS patients using the Fatigue Impact Scale (FIS). With regard to psychiatric comorbidity, the SCL-90R scores showed higher levels of somatic complaints in CFS patients than in healthy subjects, whereas augmented depressive and obsessive-compulsive symptoms were observed only in the depressed CFS subgroup. When comparing the TAS-20 scores, we observed a selective impairment in the capacity to identify feelings and emotions, as measured by the Difficulty in Identifying Feelings subscale (DIF), non-depressed CFS patients showing an intermediate score between depressed CFS and healthy controls. Finally, in terms of FIS scores, a statistical trend versus a higher fatigue severity in depressed CFS patients, with respect to non-depressed ones, was observed. In conclusion, comorbid depression in CFS significantly increased the level of psychophysical distress and the severity of alexithymic traits. These findings suggest an urgent need to address and treat depressive disorders in the clinical care of CFS cases, to improve social functioning and quality of life in such patients.
other depressive disorders and anxiety disorders do not exclude the diagnosis of CFS. Subjects with CFS show higher rates of major depression and generalized anxiety disorder when compared to the general population (4) . Furthermore, the comorbidity rate increases if subthreshold depressive symptoms are also taken into account (5) .
There are different hypotheses to justify the high rate of comorbid depression in CFS patients.
Depression may be an emotional reaction to disabling physical symptoms, as observed in other chronic fatiguing illnesses. On the other hand, depression and CFS may share common risk factors, such as an altered activation of inflammatory and oxidative pathways (6) , or a similar widespread reduction in brain 5-HTIA receptor binding potential (7) . The influence of comorbid psychiatric symptoms on clinical phenotype and long-term outcome of CFS is still debated, and the literature data seem controversial. Some Authors report that the presence of depressive symptoms in CFS patients are associated to a negative impact on healthrelated quality of life, a poorer outcome and a major severity of clinical symptoms (8) (9) . On the contrary, a recent longitudinal study did not find any significant association between comorbid depression and the clinical outcome in CFS (10) . Even though the high lifetime and current prevalence, comorbid psychiatric conditions in ' CFS patients are often undiagnosed and untreated (11) , negatively affecting socialfunctioning and quality of life.
Another controversial point regards the role of personality traits in determining an increased risk for CFS and depression onset. Alcxithymia, defined as a deficit in cognitive processing and regulation of emotions (12) has been associated to a wide range of psychiatric symptoms (13) . Alexithymic subjects have difficulty in identifying and communicating feelings, and their thinking is externally oriented, thus resulting indeficient self-regulation ofemotional and physical responses to life events and bodily sensations. Abnormal alexithymic traits have been reported in subjects affected by depressive disorders (14) , medically unexplained somatic symptoms (15) , CFS (16) and chronic medical illnesses (17) . Subjects with serious difficulties in cognitive processing and regulating emotions showed an augmented risk of hypertension and cardiovascular mortality (18) .
Identifying alexithymic traits may therefore be useful to choosing a better therapeutic intervention in subjects affected by long-lasting psychiatric and medical diseases.
The aim of the present study is to evaluate the psychophysical distress and alexithymic traits in CFS patients with and without comorbid depression.
MATERIALS AND METHODS
The Clinic of Infectious Diseases of Chieti is one of the main National Reference Centers for CFS Study in Italy. Subjects with suspected CFS are hospitali zed to receive a complete clinical, instrumental and biochemical evaluation, in order to confirm or exclude the diagnosis.
The inclusion criteria to participate in this study were : age 18-65, the presence of a medically unexplained fatigue lasting six months or more , drug-free at the moment of the evaluation, no past psychiatric diagnosis, no substance abuse in the previous 2 years and no current medical diagnosis.
Over a period of 12 months, 65 subjects (21 males , 44 females) met the inclusion criteria and were enrolled in the study. All subjects received a detailed explanation of the study design and gave their written informed consent according to the World Medical Association Declaration of Helsinki (19) : The general procedures were approved by the local Institutional Ethics Committee.
On the first day of hospitalization, the participants were psychometrically assessed by means of Symptom Checklist-90-R (SCL-90R) and Toronto Alexithymia Scale (TAS-20) . The SCL-90R (20) is a well known 90item self-report instrument to assess the psychophysical distress in psychiatric and somatic conditions. In particular, 83 items investigate nine primary symptom dimensions: Somatization (SOM), Obsessive-compulsion (OC), Interpersonal sensitivity (IS), Depression (DEP), Anxiety (ANX), Hostility (HOS), Phobic anxiety (PHOB), Paranoid ideation (PAR) and Psychoticism (PSY). The remaining seven items are related to appetite and sleep disorders. SCL-90R also provides three global distress indices: the Global Severity Index (GSI), Positive Symptom Total (PST), and Positive Symptom Distress Index (PSDI). A widely accepted cut off value is 1.0 for the SCL-90 subscales (0.7 for psychoticism) and 0.6 for the GSI.
The Toronto Alexithymia Scale (TAS-20) is the most widely used instrument to measure alexithymia levels (21) . The TAS-20 has a three-factor structure: Factor I assesses the capacity to identify feelings and to distinguish between feelings and the bodily sensations of emotional arousal (Difficulty in Identifying Feelings, DIF) ; Factor 2 reflects the inability to communicate feelings to other people (Difficulty in Describing Feelings, DDF); Factor 3 assesses Externally Oriented Thinking (EOT). In the present study the Italian validated version of the TAS-20 was used (22) .
On admission, all participants also underwent a complete medical and laboratory evaluation, following the CDC-I 994 guidelines. Impact of fatigue on activities of daily living was assessed by means of Fatigue Impact scale (FIS) (23), a self-reporting tool applied in a range of chronic disease settings including CFS . The FIS examines patients' perceptions of the functional limitations that fatigue caused over the previous month on three domains: cognitive, physical and psychosocial. Higher scores indicate that fatigue has a greater impact on the patient with more functional limitations.
On the second day of hospitalization, a Structured Clinical Interview for DSM-IV Axis I and II Disorders (SCm I and II) (24, 25) was administered to each participant by a psychiatrist, blind to the psychometric, medical and laboratory data, with the following results : a) 3 subjects met the DSM-IV criteria for an Anxiety Disorder: 2 Generalized Anxiety Disorder, I Panic Attack Disorder;
b) 17 subjects met the DSM-IV criteria for a Depressi ve Disorder: 2 Disthymia, I Major Depressive Episode with atypical features , 14 Depressive Disorder Not Otherwise Specified (NOS) ("minor depression": depressive symptoms that caused significant interference without formally satisfying criteria for a Major Depressive Episode); c) 45 subjects were free of any current psychiatric disorder.
The medical and laboratory evaluation revealed that 5 subjects were affected by an existing, but previously unidentified medical condition which may cause fatigue and were therefore excluded from the study. The other 60 participants fulfilled the CDC-I994 criteria for CFS and were divided into three groups based on psychiatric comorbidity: a) CFS with comorbid anxiety (ANX-CFS group N=3, 3 females) b) CFS with comorbid depression (DP-CFS group , N=17, 12 females) c) CFS without any psychiatric comorbidity (not DP-CFS group, N=40, 26 females).
Axis JI psychiatric comorbidity
Two subjects in the ANX-CFS group were affected by a Personality Disorder (PO) (66.7%): one Evitant PO, one Dependent PD. None of the subject in the other two groups were affected by any PD.
Due to the small sample size, data from the ANX-CFS group were not analyzed. Subjects belonging to the DP-CFS and not DP-CFS groups were asked to continue the study.
A normal comparison group (NC group, N=55, 38 females) was enrolled via public announcement. Normal controls were 18-65 years old, free from any current medical condition, any past and current Axis I and " psychiatric disorder and any pharmacological treatment. They underwent a complete medical , laboratory and psychiatric evaluation and then they were asked to complete the SCL-90R and TAS-20 questionnaires. The normal controls' psychometric data were compared to data obtained from DP-CFS and not DP-CFS groups.
Neither patients nor controls received payment for their participation in the study.
Statistical analysis
Statistical analysis was performed using Statistica 6.1 software (Statsoft Italia sri, 2003). Analysis was carried out blinded to the status of patients and controls. Categorical variables were analyzed using the chi-square test. Parametric variables were presented as mean and standard deviation, and comparisons were drawn between groups using Analysis of Variance (ANOVA) . Homogeneity of variance was assessed by means of Brown-Forsythe test.
Analysis conducted in the whole sample (patients and normal comparisons)
A 3 group (DP-CFS, not DP-CFS, NC) x 3 TAS-20 subscale (DIF, DDT, EOT) mixed ANOVA design was used to analyze the mean TAS-20 values . A 3 group (DP-CFS, not DP-CFS , NC) x 9 SCL-90R subscale (SOM, OC, IS, DEP, ANX, HOS , PHOB, PAR, PSY) mixed ANOVA design was used to analyze the mean SCL-90R values. A Global Severity Index (GSI) was also calculated and between-group differences tested by means of a Oneway ANOVA design.
Analysis limited to the patient groups
A 2 group (DP-CFS, not DP-CFS) one-way ANOVA was conducted on FIS scores and duration of illness.
To take into account the possible confounding effect of fatigue severity on SCL90-R and TAS-20 results, we entered FIS scores as a covariate into a mixed ANCOVA design. Significant effects were dissected by means of Duncan Posthoc test. When a significant between-group difference was observed, Cohen's index d-values were also calculated in order to obtain a better evaluation of the magnitude of group differences on continuous study measures.
Correlation analysis
We calculated the Spearman rank order coefficients 
CFS patients with and without comorbid depression did not significantly differ in terms of illness duration, whereas a trend versus a higher level of f atigue, as measured by Fatigue Impact scale (FIS), was observed (p=O.051).
in the DP-CFS and not-DP-CFS groups to assess any significant association between the clinical variables (FIS score, months of illness) and SCL-90R and TAS-20 results. Statistical significance was accepted at p<O.05, corrected for multip le comparisons using a Bonferroni correction. (Table 1) The patients and controls were well-matched in terms of age, gender distribution and years of education. CFS patients with and without depressive symptoms did not significantly differ in terms of months of illness. A statistical trend versus a higher FIS score in the DP-CFS group, in respect to the not-DP-CFS group was observed (p=0.05 1). (Table 11) TAS-20. A main effect group was observed: DP-CFS scored higher than both not-DP-CFS and NC. We also found a significant group x subscale interaction. The Duncan post-hoc test revealed that not-DP-CFS patients scored higher than controls and lower than DP-CFS in terms of DIF subscale, whereas no significant difference was observed for DDT and EOT subscales (Fig. 1) . The results remained significant after controlling for FIS scores: p(ANCOVA F)<O.OOI. SCL-90R. A main effect group was observed for both CGI and 9 subscales mean score: not-DP-CFS had an intermediate score between DP-CFS and NC: DP-CFS > not-DP-CFS > NC. 22 (*) 20 .... The 9 subscales analysis showed also a highly significant group x subseaIe interaction. Post-hoc comparisons found that both not-DP-CFS and DP-CFS patients scored higher than NC in terms of SOM subscale, but only DP-CFS had higher OC and DEP values in respect to NC (Fig. 2) . Results remained significant after controlling for FIS scores: p(ANCOYA F)<O.05.
RESULTS

Demographic characteristics
Analysis conducted on the whole sample (patients and normal comparisons) : psychometric results
Correlation analysis results
We did not find any significant correlation between severity of fatigue, duration of illness and SCL-90-R and TAS-20 scores in the patient groups: peR Spearman»O.05, corrected for multiple compansons.
DISCUSSION
In the present study, we found that 28.3% of subjects meeting CDC criteria for CFS (3) was affected by a comorbid depressive disorder, mostly represented by a "minor depression", categorized as "Not Otherwise Specified Depressive Disorder" in DSM-IY. A high prevalence of current and lifetime mood disorders in CFS patients in respect to the general population has already been reported (4) . Minor depression needs to be appropriately treated because of the severe impact upon social functioning and quality of life and the high risk of developing major depression (26) .
Our depressed CFS patients showed a statistical trend towards a higher impact of fatigue upon daily living activities, as measured by FIS, in respect to non-depressed patients, even though the difference did not reach statistical significance. This result may be interpreted in three different ways: I) depressive symptoms may be consequences of a more disabling fatigue; 2) depression may predict a higher level of fatigue; 3) fatigue and depression may act as independent risk factors for each other, as suggested by large longitudinal population studies (27) .
In terms ofpsychological distress, as measured by the SCL-90R, all CFS patients showed higher levels of somatic complains than normal comparisons, whereas abnormal levels ofdepressive and obsessivecompulsive symptoms were limited to the depressed CFS group. A high level of somatic complaints was also reported in subjects suffering from long-lasting somatic illnesses, thus it might be considered an aspecific measure of distress in chronic patients. The higher score in the SCL-90R DEP subscale observed in the DP-CFS patients confirmed the good sensitivity of this self-reporting tool in highlighting depressive features. An augmented rate of obsessivecompulsive symptoms in CFS patients has already been observed and associated to a lower percentage of long-term functional recovery (28) . A highly anxious, defensive way of coping was observed in CFS patients in respect to both healthy individuals and chronic diabetics (29) . A possible explanation of our results may be that the depressed CFS patients used specific obsessive-compulsive defensive mechanisms to cope with their cognitive disability. We found a significant difficulty in identifying feelings in both groups of CFS patients, as measured by DIF subscale of TAS-20. DIF subscale was associated to a poorer health-related quality of life in the general population (30) and it predicted a high number of somatic symptoms in patients reporting medically unexplained conditions (IS). Nevertheless, the results in CFS patients were discordant. Even though alexithymia is a relatively stable trait in the general population (31), some investigators consider it a state reaction (13) which mitigates painful effects in patients with somatic and psychiatric disorders. In our study, CFS patients without depressive symptoms scored higher than controls and lower than depressed CFS in terms of DIF subscale, suggesting that difficulty in identifying feelings may be a state-modulated personality trait.
We failed to find any significant correlation between alexithymic traits, psychophysical distress and fatigue severity or duration of illness. This result may be due to the small sample size or may be better explained by a complex integrated model for CFS, in which depression, alexithymic traits and fatigue are independent but partially overlapping factors (32) .
In summary, a comorbid depression disorder in CFS increased the level of psychophysical distress and the severity of alexithymic traits. These results demonstrate an urgent need to address and treat depressive disorders in the clinical care of CFS patients, to improve social functioning and quality of life. Pharmacological antidepressant treatment, however, should be limited to those patients with a comorbid depression, due to the lack of significant efficacy of antidepressants on non-psychiatric CFS symptomatology (4) .
The limits of the present study are the small sample size, thus resulting in a small statistical power, and the lack of longitudinal data. Another important limitation is that participants were hospitalized at the moment of the psychometric evaluation, thus somewhat reducing the generalizability of our findings.
